GOLDEN, Colo. — April 4, 2023 — Results of a comprehensive review of published scientific literature comparing data associated with various DNA vaccine delivery methods will be presented at the World Vaccine Congress 2023 on April 5, 2023 at 5:10 pm ET.
View
GOLDEN, Colo. — April 3, 2023 – Following completion of Phase II/III study, PharmaJet partner Gennova Biopharmaceuticals Limited has submitted data for its mRNA-based Omicron specific Covid-19 booster shot for Emergency Use Authorization (EUA) to the office of the drug controller General of India (DCGI). The submission corresponds with an
View
GOLDEN, Colo. — March 21, 2023 — PharmaJet®, a company engineering precision delivery systems that may overcome the challenges of nucleic acid vaccine delivery, today announced that its partner, Scancell, a developer of novel immunotherapies for the treatment of cancer and infectious diseases, reported positive results from their Phase 1
View
GOLDEN, Colo. — February 23, 2023 — In a review article recently published in Vaccines Journal (MDPI), Dr. Carmen Ledesma-Feliciano, Scientific Affairs Manager at PharmaJet, referencing over 25 studies, discusses multiple injection delivery methods including PharmaJet’s needle-free precision delivery systems, which enhance the clinical performance of DNA-based vaccines.
View
GOLDEN, Colo. — September 27, 2022 — PharmaJet®, a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that their latest research results will be presented at five upcoming conferences in October:
View
GOLDEN, Colo. — August 16, 2022 — PharmaJet® , a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics announced that its partner, University of Adelaide, has started a human trial of a DNA-based COVID-19 vaccine booster using the PharmaJet Tropis® Needle-free Injection
View
PharmaJet presents latest research showing Benefits of Needle-free at mRNA-Based Therapeutics Summit
GOLDEN, Colo. — July 19, 2022 — PharmaJet® , a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the mRNA-Based Therapeutics Summit on July 27, 2022. The presentation, entitled Advances in
View
GOLDEN, Colo. — July 5, 2022—PharmaJet®, a biotech company that, with their innovative needle-free technology has developed a more effective way of administering drugs and biologics to accelerate research, commercialization and public health outcomes, today announced that their latest research results were presented at the BIO International Convention in June.
View
GOLDEN, Colo. — June 7, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that the phase 3 clinical study sponsored by their partner, Zydus Lifesciences, has been published in The Lancet. The
View
Load more